Navigation Links
Northwest Secures US$1.65 Million Debt Financing
Date:11/6/2008

logies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent ovarian cancer. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, either in the U.S. or outside the U.S., statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the Company's ability to deliver its products to patients and charge p
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
2. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
3. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Northwest Secures US$4.0 Million in Debt Financing
6. Nikon Instruments Opens New Imaging Center at Northwestern University
7. Northwestern chemist investigates lost reds in Homer painting
8. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
9. Northwestern chemists take gold, mass-produce Beijing Olympic logo
10. Northwest Secures US$1.0 Million Debt Financing
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... advanced testing solutions for the detection of foodborne ... three months and full year ended December 31, ... for the quarter ended December 31, 2014 was ... quarter of 2013 and $1.5 million for the ...
(Date:3/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... certain matters, including the appointment of auditors, its annual ... 2015 (the "Meeting") was adjourned, as previously disclosed on ... a.m. ( Toronto time). The date ... previous disclosed. The Meeting will reconvene at the offices ...
(Date:3/26/2015)... DIEGO , March 26, 2015  BioNano Genomics, ... appointment of  Terry Salyer as chief commercial officer. ... highly effective, worldwide sales teams in life sciences. At ... ® System, a genome-mapping platform to assemble a ... investigate structural variations. To date, 32 institutions located in ...
(Date:3/26/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today ... fiscal 2015, which ended Feb. 28, increased 13% to ... per share in the current quarter were $0.20, compared ... increased 17% over prior year to $24,142,000, or $0.65 ... for the same period a year ago. ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... BioSpace , the leading life sciences employment and news ... marking the 7th edition. (Logo: ... organizations across the northwestern United States and western Canada. ... printed campaign map that is promoted online ...
... 2011 Funds Will be Used ... System Designed to Drive the Widespread Adoption of ... Fight Against Infectious Disease Biocartis, a ... systems designed to drive the widespread adoption of ...
... InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... commercialization of its proprietary stent platform technology, today announced ... the Company,s board of directors and the former Chairman, ... Chairman of InspireMD,s Board of Directors, effective immediately. InspireMD ...
Cached Biology Technology:BioSpace Spotlights Northwest's Life Science Community 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 3Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 4InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 2InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors 3
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... poisonous ― but it might be used as an ... Tel Aviv University researcher claims. Prof. ... Sciences is investigating new ways for developing a novel ... of scorpions. These compounds have gone through millions of ...
... Bridget (Birgitta) of Sweden that has been kept in a ... study conducted at Uppsala University reveals that the two skulls, ... (Katarina), is not from maternally related individuals. Furthermore, dating show ... Bridget and Catherine lived. The findings are published in the ...
... will greatly benefit the U.S., say scientists in an ... of America (ESA), the nation,s largest organization of ecological ... and economic benefits of biofuel production, U.S. policies need ... ecosystems. In the report, scientists Virginia Dale, Keith ...
Cached Biology News:Pinch away the pain 2Pinch away the pain 3The putative skull of St. Bridget can be questioned 2Beyond the corn field: Balancing fuel, food and biodiversity 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
... KLH-conjugated, synthetic peptide corresponding ... of human BRAF-HDAC complex protein/Lysine-specific ... Quality Assurance Routinely evaluated ... 2 years at -20°C ...
Biology Products: